Improving Outcomes for Patients With Life-Threatening Neurologic Illness
Launched by UNIVERSITY OF MARYLAND, BALTIMORE · Dec 5, 2019
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Recovery After Cerebral Hemorrhage" is studying how different brain injuries, such as bleeding in the brain, affect patients and how we can improve their care in the NeuroCritical Care Unit (NCCU). The goal is to better understand the common pathways of these injuries and gather important data that can help improve treatment outcomes for patients with serious neurological conditions. Researchers will collect various information about patients, including their medical history, test results, and treatments, to create a comprehensive database that can guide future care.
To be eligible for this trial, participants should be between the ages of 65 and 74 and have a serious neurological illness that requires intensive care, having been admitted to the NCCU within 14 days of their initial injury. Patients with prior severe neurological issues or head injuries, as well as prisoners, are excluded from participating. Those who join can expect to contribute to valuable research that may improve recovery for future patients facing similar challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • clinical diagnosis of potentially life-threatening neurological illness
- • admitted to Neuro ICU within 14 days of initial injury
- Exclusion Criteria:
- • known pre-existing neurological deficits related to a developmental disorder
- • prior severe stroke
- • prior severe dementia
- • prior severe head injury
- • prisoners
About University Of Maryland, Baltimore
The University of Maryland, Baltimore (UMB) is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, UMB leverages its extensive resources and expertise across various disciplines, including medicine, pharmacy, nursing, and social work, to contribute to groundbreaking discoveries and improve patient outcomes. Committed to ethical research practices and collaboration, UMB fosters an environment that promotes the translation of scientific knowledge into real-world applications, ultimately enhancing the well-being of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
Gunjan Y Parikh, MD
Principal Investigator
University of Maryland, Baltimore
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials